There is no specific treatment for overdose with Trilipix. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because Trilipix is highly bound to plasma proteins, hemodialysis should not be considered.

Trilipix is contraindicated in:

• patients with severe renal impairment, including those receiving dialysis [see CLINICAL PHARMACOLOGY].
• patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see WARNINGS AND PRECAUTIONS].
• patients with preexisting gallbladder disease [see WARNINGS AND PRECAUTIONS].
• nursing mothers [see Use In Specific Populations].
• patients with hypersensitivity to fenofibric acid or fenofibrate [see WARNINGS AND PRECAUTIONS].

When Trilipix is co-administered with a statin, refer to the Contraindications section of the respective statin labeling.

Last reviewed on RxList: 9/14/2012
This monograph has been modified to include the generic and brand name in many instances.